Partnering to Pioneer
Multimodal Spatial Diagnostics
Nucleai and leading research institutions are uniting multimodal AI technology and spatial biology to identify predictive biomarkers and translate discoveries into real-world diagnostic solutions.
We
Believe
Every patient’s biology is complex and unique, and we believe a dynamic AI-guided spatial map of their biopsy can lead to better treatment decisions. We are committed to powering the next generation of precision therapeutics with AI-driven spatial biomarkers and diagnostics.
Our
Approach
Our technology uses advanced spatial AI methods to analyze and interpret complex cellular interactions in a patient’s biopsy, translating them into actionable insights that can accelerate the development of life-saving treatments and diagnostics.
Our partnership with Nucleai will help us accelerate the translation of spatial biology insights into clinical practice, ultimately improving patient care.
Nigel Jamieson, Professor of Hepatobiliary and Pancreatic Surgery
University of Glasgow
Nucleai’s technology stands out by being the first spatial AI tool used by pathologists for clinical trial patient selection that is directly connected to a drug development program.
Noga Yerushalmi, PhD, Investment Director
M Ventures (Corporate Strategic Venture Arm of Merck KGaA, Darmstadt, Germany)
of the Top 20 Biopharma
0
+
clinical trial studies
0
+
prospective trial enrollment
0
Solutions Tailored to Your Needs
Powering Drug Development from Translational Research to Diagnostics
Biomarker Discovery & Validation
Biomarker Scoring
Genomic Biomarker Screening
Mechanism of Action (MoA)
Data Enrichment
Companion Diagnostics
Our
AI Technology
Our platform pioneers AI-driven spatial biomarker analysis, offering a first-of-its-kind multimodal solution. It ingests images from various modalities (H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics), conducts advanced spatial analysis, and delivers actionable insights. These insights optimize biomarker scoring, determine biomarker prevalence and mechanism of action (MoA), and predict response to therapy, revolutionizing our approach to disease diagnosis and treatment.
The Power of
AI Spatial Biomarkers
In this educational talk, Kenneth J Bloom, MD, FCAP, explains the evolution of precision medicine and how AI-driven spatial biomarkers can power the next-generation of therapeutics and improve patient outcomes.
Data and Institutional Partners
Investors
Join Us in
Transforming Patient Care
At Nucleai, we bring together leading minds in pathology, medicine, biology, engineering, and artificial intelligence to tackle the most complex challenges in healthcare, with the goal of transforming patient care. Come join our team to revolutionize precision medicine.